Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells

BACKGROUND: Doxorubicin is the chemotherapeutic drug of choice in osteosarcoma treatment, but its cumulative administration causes dilated cardiomyopathy. Combination therapy represents a potential strategy to reduce the therapeutic dosage of the chemotherapeutic agent and minimize its side effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Kazantseva, Liliya, Becerra, José, Santos-Ruiz, Leonor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786785/
https://www.ncbi.nlm.nih.gov/pubmed/34427908
http://dx.doi.org/10.1007/s43440-021-00324-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786785/
https://www.ncbi.nlm.nih.gov/pubmed/34427908
http://dx.doi.org/10.1007/s43440-021-00324-1

Ejemplares similares